Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.
No takes yet. Share an insight, caveat, or question.
Huck et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: